{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:25:02Z","timestamp":1764433502753,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>PRAME (PReferentially expressed Antigen in MElanoma) is a cancer testis antigen that is frequently expressed in melanoma compared to benign melanocytic proliferations and nevi. However, the interpretation of the intensity and distribution of PRAME immunostaining is not standardized a lot, which makes interpretation difficult. PRAME-stained histological slides of superficial spreading melanomas (SSM) and dysplastic nevi (DN) were digitized and analyzed using the digital pathology and image platform QuPath. t-tests and ROC AUCs were performed with SPSS. A p-value of &lt;0.05 was used for statistical significance, and a ROC AUC score of &gt;0.8 was considered a good result. A cut-off score was defined in an evaluation cohort and subsequently analyzed in an independent validation cohort. In total, 81 PRAME-stained specimens were included. The evaluation cohort included 32 (50%) SSM and 32 (50%) DN, and the mean of PRAME-positive cells\/mm2 for the entire lesion was 455.3 (SD 428.2) in SSM and 60.5 (SD 130.1; p &lt; 0.001) in DN. The ROC AUC of PRAME-positive cells of the entire lesion was 0.866, and in the epidermis it was 0.901. The defined cut-off score to distinguish between DN and SSM was 97.67 cells\/mm2. In the validation cohort, 16 out of 17 cases (94.1%) were correctly classified by the cut-off score. The computer-aided assessment of PRAME immunostaining is a useful tool in dermatopathology to distinguish between DN and SSM. Lesions with a moderate expression and indifferent morphologic features will remain a challenge for dermatopathologists.<\/jats:p>","DOI":"10.3390\/ijms24076388","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T02:03:53Z","timestamp":1680055433000},"page":"6388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-7533","authenticated-orcid":false,"given":"Elias A. T.","family":"Koch","sequence":"first","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7136-6489","authenticated-orcid":false,"given":"Michael","family":"Erdmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin","family":"Kiesewetter","sequence":"additional","affiliation":[{"name":"MVZ Pathology, Sozialstifung Bamberg, 96049 Bamberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schliep","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-1825","authenticated-orcid":false,"given":"Markus V.","family":"Heppt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"ref_1","first-page":"9742","article-title":"Immune-phenotypical markers for the differential diagnosis of melanocytic lesions","volume":"8","author":"Botti","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/cup.13648","article-title":"Immunohistochemistry utilization in the diagnosis of melanoma","volume":"47","author":"Dinehart","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2147\/CCID.S333376","article-title":"Comparison of SOX-10, HMB-45, and Melan-A in Benign Melanocytic Lesions","volume":"14","author":"Dass","year":"2021","journal-title":"Clin. Cosmet Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/cup.12564","article-title":"Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations","volume":"42","author":"Rodic","year":"2015","journal-title":"J. Cutan. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/cup.12880","article-title":"5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms","volume":"44","author":"Lee","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-0560.2008.01154.x","article-title":"p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma","volume":"36","author":"Hilliard","year":"2009","journal-title":"J. Cutan. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.pathol.2022.05.012","article-title":"Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics","volume":"54","author":"Rawson","year":"2022","journal-title":"Pathology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes","volume":"7","author":"Roszik","year":"2017","journal-title":"Clin. Sarcoma Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45352","DOI":"10.18632\/oncotarget.9977","article-title":"PRAME expression and promoter hypomethylation in epithelial ovarian cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","article-title":"Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study","volume":"11","author":"Pujol","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cazzato, G., Mangialardi, K., Falcicchio, G., Colagrande, A., Ingravallo, G., Arezzo, F., Giliberti, G., Trilli, I., Loizzi, V., and Lettini, T. (2022). Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study. Genes, 13.","DOI":"10.3390\/genes13030545"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/ajcp\/aqab200","article-title":"Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis","volume":"157","author":"Ricci","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e12770","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/cup.14000","article-title":"The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors","volume":"48","author":"Alomari","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cup.14245","article-title":"PRAME immunohistochemistry of spitzoid neoplasms","volume":"49","author":"Koh","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cup.13818","article-title":"PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features","volume":"47","author":"Raghavan","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gassenmaier, M., Hahn, M., Metzler, G., Bauer, J., Yazdi, A.S., Keim, U., Garbe, C., Wagner, N.B., and Forchhammer, S. (2021). Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas. Cancers, 13.","DOI":"10.3390\/cancers13153864"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/cup.14226","article-title":"PRAME expression in melanocytic lesions of the nail","volume":"49","author":"Parra","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/cup.14286","article-title":"PRAME expression is similar in scar and desmoplastic melanoma","volume":"49","author":"Plotzke","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/cup.13916","article-title":"Aberrant expression of HMB45 and negative PRAME expression in halo nevi","volume":"48","author":"Ruby","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/cup.13958","article-title":"The utility of PRAME staining in identifying malignant transformation of melanocytic nevi","volume":"48","author":"Lohman","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/cup.13876","article-title":"PRAME expression in 155 cases of metastatic melanoma","volume":"48","author":"Gradecki","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000524051","article-title":"Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas","volume":"8","author":"Ahmadian","year":"2022","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/DAD.0000000000001885","article-title":"Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms","volume":"43","author":"Googe","year":"2021","journal-title":"Am. J. Dermatopathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/his.14312","article-title":"PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna","volume":"78","author":"Gradecki","year":"2021","journal-title":"Histopathology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/DAD.0000000000001607","article-title":"Differential Expression of Cancer Testis Antigens on Lentigo Maligna and Lentigo Maligna Melanoma","volume":"42","author":"Tio","year":"2020","journal-title":"Am. J. Dermatopathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAI.0000000000000972","article-title":"HMB45\/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A\/PRAME)","volume":"30","author":"Grillini","year":"2022","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/cup.14212","article-title":"Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions","volume":"49","author":"Olds","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME Expression in Melanocytic Tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.surg.2015.12.029","article-title":"ROC-ing along: Evaluation and interpretation of receiver operating characteristic curves","volume":"159","author":"Carter","year":"2016","journal-title":"Surgery"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:05:23Z","timestamp":1760123123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076388"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076388","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}